Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) will participate in the KeyBanc Capital Markets Healthcare Forum with a virtual Q&A on March 17, 2026 at 11:15 a.m. ET. A live webcast will be available on the company's investor relations site and will be archived for later replay.
Details
News Market Reaction – RPID
On Mar 11, the first trading day after this news, RPID closed 6.05% above the previous close.
Data tracked by StockTitan Argus for the Mar 11 session.
Key Figures
- KeyBanc forum date
- March 17, 2026
- Scheduled virtual Q&A session with host analyst
- Event time
- 11:15 a.m. Eastern Time
- Start of virtual Q&A session at KeyBanc Healthcare Forum
Historical Context
-
Announcement of TD Cowen healthcare conference presentation and webcast details.
-
Scheduling of Q4 and full-year 2025 results release and webcast.
-
Inducement RSUs and options granted to new employees under Nasdaq rules.
-
Record preliminary unaudited Q4 and 2025 revenue and system placements.
-
Notice of J.P. Morgan Healthcare Conference presentation and webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the KeyBanc Capital Markets Healthcare Forum.
The Company is scheduled to participate in a virtual question and answer session with the host analyst on Tuesday, March 17, 2026, at 11:15 a.m. Eastern Time. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts, and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications mbeaulieu@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.